iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

iVeena在B-2系列融资中获得300万美元，以加速针对近视的IVMED-85的开发

Jerry Hu, M.D. appointed to Board of Directors

Jerry Hu医学博士被任命为董事会成员

SALT LAKE CITY, February 5, 2025-- iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its fully subscribed Series B-2 financing of $3 million.

盐湖城，2025年2月5日——iVeena Delivery Systems Inc.（“iVeena”）是一家推进IVMED-85治疗小儿近视的生物制药公司，今天宣布已完成300万美元的B-2系列全额认购融资。

This investment will support iVeena’s pursuit of advancing their innovative pediatric myopia program. All IND-enabling studies are well underway supporting a targeted IND submission in H1-2025.

这项投资将支持iVeena推进其创新的儿科近视项目。所有支持IND的研究都在进行中，支持在2025年上半年有针对性地提交IND。

“We are pleased to welcome Dr. Jerry Hu to our Board as an independent director,” said President and Founder, Bala Ambati, M.D., Ph.D., MBA. “Dr. Hu is a world-renowned ophthalmologist who stands at the forefront of cutting-edge ophthalmic innovations bringing significant value to our long-term strategy.”.

“我们很高兴欢迎胡杰瑞博士作为独立董事加入我们的董事会，”总裁兼创始人巴拉·安巴蒂（BalaAmbati），医学博士，博士，MBA说道。“胡博士是世界著名的眼科医生，他站在前沿眼科创新的前沿，为我们的长期战略带来了重大价值。”。

About IVMED-85

关于IVMED-85

IVMED-85 is a daily eye drop that strengthens scleral and corneal collagen crosslinks through LOX activation, potentially leading to improved refraction and a decrease in the rate of axial elongation. IVMED-85 is expected to begin a Phase 2 clinical study in progressive myopia in 2025.

IVMED-85是一种每日滴眼液，通过LOX激活增强巩膜和角膜胶原交联，可能导致屈光度改善和轴向伸长率降低。IVMED-85有望于2025年开始进行性近视的2期临床研究。

About iVeena

关于iVeena

iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive diseases. iVeena has licensed its lead asset to Glaukos Corporation, IVMED-80, an Orphan Drug Designated eye drop for keratoconus. iVeena is developing IVMED-85, a first in class, investigational eyedrop formulation for pediatric myopia..

iVeena Delivery Systems，Inc.是一家私营的临床阶段眼科公司，开发针对屈光不正疾病的疾病缓解药物创新。iVeena已将其主要资产授权给Glaukos Corporation，IVMED-80，一种孤儿药，指定用于圆锥角膜的滴眼液。iVeena正在开发IVMED-85，这是一种一流的用于儿童近视的研究性滴眼液配方。。

Contact:

联系人：

Corporate Contact:

公司联系人：

Michael Burr, MS, MBA

Michael Burr，硕士，MBA

Vice President of Product Development

产品开发副总裁

mburr@iveenamed.com

mburr@iveenamed.com